Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...

The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic ...

The deals are expected to shorten manufacturing timelines for cell therapies and reduce administration times for oncology ...

Dr. Dina Radenkovic, CEO of Gameto, identifies the main contributors to the gap in in women's health innovation.

Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses how the focus of technology development is shifting toward ensuring safety and continuous hearing for children.

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

A panel discussion at the Global Life Science Partnering and Investor Conference discusses various strategies and trends in ...

Traditional approaches to benchmarking brand performance have struggled to keep pace with industry dynamics. While individual ...

Immunotherapy pioneer Mark Frohlich, MD, CEO of Indapta Therapeutics, discusses the promise of harnessing natural killer ...

John Arena is interim president of global pharma services at Cencora, managing a team that offers a broad range of solutions ...

Deal to acquire Covis is expected to expand Azurity’s portfolio across multiple complex dosage forms and key therapeutics ...